Abstract:ID 95401 Poster Board 482 Objectives/Goals: Renal fibrosis is an outcome of chronic kidney disease that affects approximately one-tenth of the global community. Its pathogenesis and progression are highly multi-factorial, likely demanding a need to target various mechanisms for providing better treatment. Using an animal model of renal fibrosis, we sought to test the therapeutic response of TK-850, an experimental drug that acts as a dual-inhibitor of transforming growth factor beta receptor 1 (TGFβR1) and mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). Both serine/threonine kinases are associated with inducing pro-inflammatory and pro-fibrotic responses. Methods/Study Population: To assess the possible renal anti-fibrotic effects of TK-850, we performed a preclinical study using 8-10-week-old male and female C57BL/6 mice, who underwent unilateral ureteral obstruction (UUO) surgery for inducing renal fibrosis. Rodents either had UUO only (control), were administered TK-850 prior to and following UUO (UUO-P, 20 mpk/d/ip), or administered TK-850 following UUO (UUO-I, 20 mpk/d/ip). In either case, the kidneys and blood were collected ten days post-UUO for histopathological evaluation and biochemical analysis. Fibrosis of the kidneys was evaluated from renal hydroxyproline estimation and Picrosirius red stain for assessing collagen deposition. Results/Anticipated Results (700-character limit): As a result of UUO, both male and female mice showed similar renal hydroxyproline levels, 5.4 ± 0.41 μg/10mg, n = 5 and 5.5 ± 0.50 μg/10mg, n = 5, respectively, in comparison to the contralateral (control) kidney, 2.9 ± 0.14 μg/10mg, n = 10. Prophylactic and interventional administration of TK-850 significantly reduced hydroxyproline levels (UUO-P: 3.4 ± 0.24 μg/10mg, n = 10; UUO-I: 4.30 ± 0.20 μg/10mg, n = 10). Histological assessment of kidney injury (UUO) revealed increased collagen deposition (17.1 ± 0.43% collagen positive area, n = 10) in comparison to the non-injured, control kidney (2.0 ± 0.23%, n = 10). TK-850 treatment was also shown to significantly reduce collagen deposition in UUO-P (10.5 ± 0.38%, n = 10) and UUO-I (13.1 ± 0.25%, n = 10) mice. Both biochemical and histological responses with and without drug treatment were gender neutral. Discussion/Significance of Impact (300-character limit): In summary, our results show a positive effect of TK-850 administration to reduce kidney injury, supporting the notion of its use as a potential therapeutic compound. The results herein could also affirm the idea of having a concerted pharmacotherapeutic approach to treat such complex diseases. Research reported in this abstract was supported by a Post-Doctoral TL1 Award from National Institutes of Health under grant numbers TL1 TR003109 and UL1 TR003107.

Oral administration of GW788388, an inhibitor of TGF-|[beta]| type I and II receptor kinases, decreases renal fibrosis

Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis

Oral administration of GW788388, a kinase inhibitor of the TGF-β type I and type II receptors, reduces renal fibrosis in db/db mice

Fluorofenidone Inhibits TGF-beta1 Induced CTGF Via MAPK Pathways in Mouse Mesangial Cells.

Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related molecules

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

Latent TGF-β1 Protects Against Diabetic Kidney Disease Via Arkadia/Smad7 Signaling

Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGF{beta}R1/MAP4K4

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

EGCG targeting Notch to attenuate renal fibrosis via inhibition of TGFβ/Smad3 signaling pathway activation in streptozotocin-induced diabetic mice.

SB-525334 ameliorates renal injury in diabetic kidney disease mouse model via suppressing inflammation

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II/TGFβ signaling in diabetic mice

GSK3β-dependent Lysosome Biogenesis: an Effective Pathway to Mitigate Renal Fibrosis with LM49

Evaluation of the novel ALK5 inhibitor EW-7197 on therapeutic efficacy in renal fibrosis using a three-dimensional chip model

Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen

Low-dose of Multi-Glycoside of Tripterygium Wilfordii Hook. F., a Natural Regulator of TGF-β1/Smad Signaling Activity Improves Adriamycin-Induced Glomerulosclerosis in Vivo.

The Renal TGF-β System in the db/db Mouse Model of Diabetic Nephropathy

Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage

New EGFR Inhibitor, 453, Prevents Renal Fibrosis in Angiotensin II-stimulated Mice

387-P: Novel Mitochondrial Complex I Modulator Reduces Diabetes-Associated Expression of Inflammation and Fibrosis Markers in Human Proximal Tubular Epithelial Cells